Recent advances in the management of pheochromocytoma and paraganglioma

Hypertens Res. 2020 Nov;43(11):1141-1151. doi: 10.1038/s41440-020-0531-0. Epub 2020 Aug 11.


Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that cause refractory hypertension and hypertensive crisis. Although metastatic disease accounts for 30% of PPGLs, the diagnosis of malignancy is difficult without the presence of metastatic lesions. Here, we review several advancements in the diagnosis and treatment of PPGL. A nationwide epidemiological survey in Japan revealed that the annual number of patients with PPGL was 3000, which was higher than that reported previously. While plasma and urine fractionated metanephrines are recommended for use in specific biochemical testing for diagnosis, creatinine-corrected fractionated metanephrines in spot urine samples that had been widely used in Japan as a convenient screening test were shown to be as useful as 24-h urine fractionated metanephrines. Regarding imaging studies, a more specific functional imaging for PPGLs, 68Ga DOTATATE, was newly developed. 68Ga DOTATATE provides a clear image with high sensitivity and specificity. Currently, PASS or GAPP histological scores and SDHB immunostaining are clinically used to attempt to discriminate benign from malignant tumors. However, since this distinguishing process remains difficult, all cases were classified as malignant with the possibility of metastasis in the WHO classification of endocrine tumors updated in 2017. Approximately 60% of PPGLs have germline mutations in PPGL-related genes. Currently, the genes are classified into two clusters based on their mechanism for the etiology of tumorigenesis. Based on the possible mechanisms of tumor development associated with gene mutations, several molecular target drugs are under evaluation to explore more promising treatments for malignant PPGL.

Keywords: Catecholamine; Functional imaging; Germline mutation; Malignant pheochromocytoma; Molecular targeted therapy.

Publication types

  • Review

MeSH terms

  • Adrenal Gland Neoplasms / diagnostic imaging
  • Adrenal Gland Neoplasms / epidemiology
  • Adrenal Gland Neoplasms / genetics
  • Adrenal Gland Neoplasms / therapy*
  • Endocrinology / trends
  • Genetic Testing
  • Humans
  • Incidental Findings
  • Molecular Targeted Therapy
  • Paraganglioma, Extra-Adrenal / diagnostic imaging
  • Paraganglioma, Extra-Adrenal / epidemiology
  • Paraganglioma, Extra-Adrenal / genetics
  • Paraganglioma, Extra-Adrenal / therapy*
  • Pheochromocytoma / diagnostic imaging
  • Pheochromocytoma / epidemiology
  • Pheochromocytoma / genetics
  • Pheochromocytoma / therapy*
  • Positron-Emission Tomography